Table 1.
Univariate analysis of risk factors for candidemias by biofilm-forming (BF) and non-biofilm-forming (NBF) isolates.
Table 2.
Logistic regression analysis of risk factors for candidemias by biofilm-forming (BF) and non-biofilm-forming (NBF) isolates.
Figure 1.
Survival among patients with Candida bloodstream infection (CBSI) at 30 days.
Patients were grouped according to the biofilm-forming (BF) or non-biofilm-forming (NBF) Candida isolate (for all CBSIs), and according to receiving of highly active anti-biofilm (HAAB) or non-HAAB antifungal therapy (for BF CBSIs only). P-values for statistically significant differences between the groups are shown.
Figure 2.
Hospital length of stay (LOS) following the Candida bloodstream infection (CBSI) onset in all (white box-plots) or surviving (grey box-plots) patients.
Patients were grouped according to the biofilm-forming (BF) or non-biofilm-forming (NBF) Candida isolate (for all CBSIs), and according to receiving of highly active anti-biofilm (HAAB) or non-HAAB antifungal therapy (for BF CBSIs only). Lines inside the boxes indicate the median values, whereas upper and lower limits of the boxes and whiskers indicate the interquartile and total ranges, respectively. P-values for statistically significant differences between the groups are shown.
Table 3.
Comparison between patients with biofilm-forming (BF) candidemia or non-biofilm-forming (NBF) candidemia in the matched cohort study.